ELUT vs XTNT vs NVCR vs LMAT

For growth investors, Xtant Medical Holdings, Inc.

(XTNT) is the stronger pick with 28. 4% revenue growth year-over-year, versus -49. 6% for Elutia Inc. (ELUT). Elutia Inc. (ELUT) offers the better valuation at 0. 8x trailing P/E, making it the more compelling value choice. Analysts rate NovoCure Limited (NVCR) a "Buy" — based on 15 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Elutia Inc.

(ELUT) is the cheapest at 0. 8x versus LeMaitre Vascular, Inc. at 42. 8x.

Over the past 5 years, LeMaitre Vascular, Inc.

(LMAT) delivered a total return of +118. 2%, compared to -91. 4% for Elutia Inc. (ELUT). Over 10 years, the gap is even starker: LMAT returned +608. 6% versus XTNT's -97. 8%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Elutia Inc.

(ELUT) is the lower-risk stock at -0. 11β versus NovoCure Limited's 2. 20β — meaning NVCR is approximately -2170% more volatile than ELUT relative to the S&P 500. On balance sheet safety, Elutia Inc. (ELUT) carries a lower debt/equity ratio of 27% versus 85% for NovoCure Limited — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Xtant Medical Holdings, Inc.

(XTNT) is pulling ahead at 28. 4% versus -49. 6% for Elutia Inc. (ELUT). On earnings-per-share growth, the picture is similar: Elutia Inc. grew EPS 169. 4% year-over-year, compared to 21. 8% for NovoCure Limited. Over a 3-year CAGR, XTNT leads at 28. 5% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Elutia Inc.

(ELUT) is the more profitable company, earning 434. 2% net margin versus -20. 8% for NovoCure Limited — meaning it keeps 434. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LMAT leads at 27. 2% versus -149. 8% for ELUT. At the gross margin level — before operating expenses — NVCR leads at 74. 5%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

Analyst consensus price targets imply the most upside for NVCR: 99.

0% to $33. 50.

In this comparison, LMAT (0.

7% yield) pays a dividend. ELUT, XTNT, NVCR do not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, LeMaitre Vascular, Inc.

(LMAT) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 57), 0. 7% yield, +608. 6% 10Y return). NovoCure Limited (NVCR) carries a higher beta of 2. 20 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (LMAT: +608. 6%, NVCR: +30. 3%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: ELUT is a small-cap deep-value stock; XTNT is a small-cap high-growth stock; NVCR is a small-cap quality compounder stock; LMAT is a small-cap quality compounder stock. LMAT pays a dividend while ELUT, XTNT, NVCR do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.